

# **Standard Operating Procedures**

## **for the 16<sup>th</sup> merger**

### **Data Management**

#### **Data Collection on Adverse Events of Anti-HIV Drugs**

#### **The D:A:D study**

# **D:A:D**

#### **Participating cohort studies:**

EuroSIDA, (20 European countries); Swiss HIV Cohort Study, (Switzerland);  
ICONA, (Italy); ATHENA Cohort, (The Netherlands); BASS Cohort, (Spain);  
CPCRA, (USA); Nice Cohort, (France); Aquitaine Cohort, (France);  
HivBIVUS, (Sweden); Brussels St. Pierre Cohort, (Belgium);  
Australian HIV Observational Database, (Australia);

#### **Authors:**

**Casper Møller Frederiksen** ([casper.moeller.frederiksen@regionh.dk](mailto:casper.moeller.frederiksen@regionh.dk))

Rigshospitalet, University of Copenhagen  
CHIP, Department of Infectious Diseases,  
Section 2100, Finsencentret  
Blegdamsvej 9  
DK-2100 Copenhagen, Denmark

Phone: +45 35 45 57 57  
Fax: +45 35 45 57 58



<b>1</b>	<b>Introduction to the D:A:D SOP for the 16th Merger .....</b>	<b>3</b>
<b>2</b>	<b>General D:A:D Background .....</b>	<b>3</b>
<b>3</b>	<b>Timing of the 15th and Subsequent Mergers .....</b>	<b>3</b>
<b>4</b>	<b>What is New or Different for this Merger? .....</b>	<b>3</b>
4.1	Renaming/restructuring the tables to match HICDEP .....	3
4.2	tblBAS: Added field names .....	4
4.3	tblVIS: Visit related information .....	<b>Fejl! Bogmærke er ikke defineret.</b>
4.4	tblCEP: tblAE renamed to tblCEP .....	<b>Fejl! Bogmærke er ikke defineret.</b>
4.5	tblCEP: NADC renamed to NADM.....	<b>Fejl! Bogmærke er ikke defineret.</b>
<b>5</b>	<b>What should be Submitted .....</b>	<b>4</b>
<b>6</b>	<b>D:A:D Data-sections.....</b>	<b>4</b>
6.1	Demographic, Clinical, and Background Information [tblBAS] .....	4
6.2	Overlap: Cross-Cohort Identification [tblOVERLAP] .....	4
6.3	Visit-related Data [tblVIS and tblVIS_DAD] .....	4
6.4	Treat. for/influencing Cardiovascular Risks (Status) [tblVIS_DAD] .....	5
6.5	Treat. for/influencing Cardiovascular Risks (Drugs) [tblMED] .....	5
6.6	Clinical Events and Procedures [tblCEP] .....	5
6.7	Blood Pressure [tblLAB_BP].....	5
6.8	Laboratory Data [tblLAB] .....	5
6.9	CD4 measurements [tblLAB_CD4] .....	5
6.10	RNA measurements [tblLAB_RNA] .....	5
6.11	Virology/Serology: Hepatitis [tblLAB_VIRO] .....	5
6.12	Use of Anti-retroviral Treatments [tblART] .....	5
6.13	Other HIV-related Treatments [tblMED] .....	5
6.14	Severe Opportunistic Infections & Malignancies [tblDIS] .....	6
6.15	Lost to follow-up and deaths [tblLTFU] .....	6
<b>7</b>	<b>D:A:D Data Format .....</b>	<b>6</b>
7.1	<i>Blank</i> Values .....	6
7.2	Unknown Values.....	6
<b>8</b>	<b>Data File Transfers to the D:A:D Co-ordinating Centre .....</b>	<b>6</b>
<b>9</b>	<b>Error and Discrepancy Reporting .....</b>	<b>7</b>
	<b>Appendix .....</b>	<b>8</b>
1.	tblBAS: Demographic, Clinical and Background Information .....	9
2.	tblBAS_DAD: Enrolment .....	9
3.	tblOVERLAP: Cross-Cohort Identification .....	11
5.	tblVIS_DAD: Additional Visit-related Data .....	12
6.	tblCEP: Adverse Events .....	13
8.	tblLAB: Laboratory Values.....	14
9.	tblLAB_CD4: CD4 Measurements .....	15
10.	tblLAB_RNA: RNA Measurements .....	16
11.	tblLAB_VIRO: Virology/Serology: Hepatitis and HIV-tests .....	17
12.	tblART: Use of Anti-Retroviral Treatments .....	18
13.	tblMED: Other HIV-Related and Cardiovascular Treatments .....	22
14.	tblDIS: Severe Opportunistic Infections & Malignancies.....	25
15.	tblLTFU: Lost to Follow-Up and Deaths .....	27

# 1 Introduction to the D:A:D SOP for the 16th Merger

The D:A:D structure, to the extent possible, conforms to the HICDEP protocol. (See the latest version of HICDEP: HIV Cohorts Data Exchange Protocol at the CHIP website: [www.cphiv.dk](http://www.cphiv.dk).) Changes and additions are always part of the on-going process for projects that extend over time, and the D:A:D is no exception.

## 2 General D:A:D Background

The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) is a prospective multi-cohort study of HIV-infected persons under active follow up. The primary purpose of the study is to assess the incidence of myocardial infarction among HIV/AIDS patients who are receiving anti-retroviral therapy. This, in turn, will allow us to investigate whether treatment with anti-retroviral drugs is associated with development of cardio-vascular disease, an evaluation of long-term side effects.

The study began in 1999 with eleven cohorts worldwide participating with an initial enrolment of more than 23,000 patients. At the 5<sup>th</sup> merger, an additional 10,000 patients were included. At the 10<sup>th</sup> merger an additional 16,500 thousand patients were enrolled. The project is scheduled to continue at least until the completion of the 17th merger in 2016.

The centralized data processing for D:A:D takes place once a year. Each cohort gathers and computerizes its own data; subsequently it is merged in a database in Copenhagen. The core data in the study is information on incident cases of cardiovascular disease, which are reported immediately to the local cohort coordinating office by fax, using event reporting forms (available at [www.cphiv.dk](http://www.cphiv.dk)).

The data collection also includes information on risk factors for cardiovascular disease, such as previous myocardial infarction or stroke, hereditary tendency, smoking status, diabetes mellitus, dyslipidemia and hypertension. At the 5<sup>th</sup> merger, data on viral hepatitis testing became part of the collection process and at the 7<sup>th</sup> glucose measurements were introduced. At the 8<sup>th</sup> merger we began collecting serum creatinine readings. At the 10<sup>th</sup> merger we greatly expanded the Adverse Events table to collect new clinical endpoints. At the 12<sup>th</sup> merger bilirubin measurements have been added to the lab-measurements collected.

## 3 Timing of the 16th and Subsequent Mergers

The deadline for data submission for this merger is Friday, May 29<sup>th</sup> 2015. During the 6 weeks after the submission of data, until around mid-July, we will send out error and discrepancy information in the form of small databases. We will spend the next 1½ months processing your response to these reports and working closely with you to clean the data. The cleaning of the data should be completed around September 1<sup>st</sup>.

The data transfer date for the 17<sup>th</sup> merger is planned for Tuesday, May 31<sup>st</sup> 2016

## 4 What is New or Different for this Merger?

### 4.1 Renaming/restructuring the tables to match HICDEP

All tables and fields that match the HIV Cohorts Data Exchange Protocol (HICDEP) are (re-)named according to HICDEP 1.70 (*in some cases HICDEP 1.80*). More details of the protocol can be found at <http://hicdep.org/>. Some tables have been split into two tables - a HICDEP only and a D:A:D specific table. The purpose of this is to ease the burden for the data managers who contribute to more than one study so that the codes set up to produce the HICDEP compliant table can be

reused for all studies, since the D:A:D specific fields are moved to a separate table. The DAD specific tables have the suffix \_DAD to distinguish them.

## 4.2 **tbLAB, tbLAB\_CD4, tbLAB\_VIRO, tbLAB\_RNA: Added the “VERIFIED” field**

The variable VERIFIED is used to indicate that outliers (laboratory values or results) have been verified. The field was requested by data managers at the last face-2-face meeting. Please note the DDM-tool require this field.

## 4.3 **Leishmaniasis and Microsporidiosis diarrhoea: Moved from tbIDIS to tbICEP**

Please note that Leishmaniasis (LEIS (visceral)) and Microsporidiosis diarrhoea (MCDI (dur. > 1 month)) will be moved from the “AIDS-defining table” (tbIDIS) to the “non-AIDS-defining table” (tbICEP).

# 5 What should be Submitted

For all Cohorts, (I, II, and III), please submit **all** the data you have--**past and present**--for each patient. This also refers to the new clinical endpoints (chronic liver disease, end stage renal disease, and non-AIDS defining malignancies). At the very minimum, **ALL** patients must appear in the BAS (demographic, clinical, and background information) table including those who have died, dropped-out, been lost to follow-up, or not shown up for their 14th merger visit.

# 6 D:A:D Data-sections

## 6.1 **Demographic, Clinical, and Background Information [tbIBAS]**

Each patient, whether seen at the 16th merger or not, should appear once in this table.

Please make sure that the enrolment date, ENROL\_D, is the date that the patient enrolled in the local cohort. (This has been misinterpreted by some at earlier mergers.) Participation in the D:A:D study begins with the baseline visit date.

Some cohorts are prohibited from reporting certain types of data such as date of birth, origin or race. For ORIGIN, please leave these fields *blank*. For RACE, use the code “98”. For BIRTH\_D please code the birth date as the unknown date for the birth year (01/07/XXXX).

The structure of this table has changed for this merger – HIVN\_D and HIVP\_D have been removed and the ENROL variable has been moved into its own table (tbIBAS\_DAD) since this is not a HICDEP field. See the Appendix for the details.

## 6.2 **Overlap: Cross-Cohort Identification [tbIOVERLAP]**

Patients who are known to be in other cohorts participating in D:A:D should be entered in this table, once for each cohort. If none of your patients is a member of another cohort participating in D:A:D, please do not submit this table. See the Appendix for details.

## 6.3 **Visit-related Data [tbIVIS and tbIVIS\_DAD]**

Please provide visit data for all visits, not just from the last visit. At this merger the Visit table has been divided into two tables – one for core HICDEP variables (tbIVIS), and one for the specific D:A:D variables (tbIVIS\_DAD). See the Appendix for details.

## 6.4 Treat. for/influencing Cardiovascular Risks (Status) [tblVIS\_DAD]

Please submit the data from all visits, not just from the last visit. At this merger this information is added to the tblVIS\_DAD table, rather than having its own table, as the information is visit-date related, but not part of the core HICDEP variables. Please note that in submitting tblVIS\_DAD you are not required to submit the values regarding Cardiovascular Treatment if you have not at previous mergers been submitting the CAR table. See the Appendix for details.

## 6.5 Treat. for/influencing Cardiovascular Risks (Drugs) [tblMED]

At this merger the medication for cardiovascular diseases are added to the tblMED table in accordance with the HICDEP protocol. For each drug treatment episode, please provide treatment start date and treatment end date. If the treatment is on-going, please leave the end date field *blank*. The different drug interventions are identified with the ATC code in the MED\_ID field. See the Appendix for details.

## 6.6 Clinical Events and Procedures [tblCEP]

The table tblAE has been renamed as it has grown to include event types that would not necessarily be classified as Adverse Events. Along with this renaming, the fields have also been renamed from AE\_xx to CEP\_xx. See the Appendix for details.

## 6.7 Blood Pressure [tblLAB\_BP]

The structure of this table is unchanged for this merger. See the Appendix for details.

## 6.8 Laboratory Data [tblLAB]

Please note the new VERIFIED field. See the Appendix for details.

## 6.9 CD4 measurements [tblLAB\_CD4]

Please note the new VERIFIED field. See the Appendix for details.

## 6.10 RNA measurements [tblLAB\_RNA]

Please note the new VERIFIED field. See the Appendix for details.

## 6.11 Virology/Serology: Hepatitis [tblLAB\_VIRO]

Please note the new VERIFIED field. See the Appendix for details.

## 6.12 Use of Anti-retroviral Treatments [tblART]

The structure of this table is unchanged for this merger. Each anti-retroviral treatment is identified by its ATC code, which can be up to 12 characters. If the patient has been given ART, enter the proper ATC code in the ART\_ID field followed by ART\_SD (start date) and ART\_ED (stop date). If the patient is currently undergoing treatment, the stop date should be *blank*. See the Appendix for details.

## 6.13 Other HIV-related Treatments [tblMED]

The structure of this table is unchanged for this merger. The Cardiovascular treatments have been moved to this table and the codes added. Each treatment is identified by an ATC code that can be up to 12 characters. These codes should be entered in the MED\_ID field if the patient has been treated with the corresponding drug, followed by the MED\_SD (start date) and MED\_ED (end date). If the patient is currently undergoing treatment, please leave the end date *blank*. Please notice that a few of the treatments have the same ATC code and, perhaps what is more important, some of the old codes have been split into two separate ATC codes. See the Appendix for details.

## 6.14 Severe Opportunistic Infections & Malignancies [tbIDIS]

The structure of this table is unchanged for this merger. See the Appendix for details.

## 6.15 Lost to follow-up and deaths [tbLTFU]

The structure of this table is unchanged for this merger. See the Appendix for details.

# 7 D:A:D Data Format

Please submit your data using the D:A:D formats described in the tables in the Appendix.

## 7.1 Blank Values

A “.” represents a missing value in SAS. SAS will automatically convert a *blank* field to the missing value code “.”. Where a variable is not applicable, or not used, (such as the fasting variable for haemoglobin measurements in the LAB\_N table), leave the field *blank*. (This also applies to fields where data collection is legally prohibited, such as BIRTH\_D for some cohorts.) If data is missing where a response is required or available, the cohort validation programs should detect this and this information will become part of the database for errors and discrepancies.

## 7.2 Unknown Values

The category “unknown” indicates that the information needed is unknown or purposely left as missing. The codes 9, 99, and 999 are used to designate this category. Please see the tables in the Appendix for the specific coding.

The date 1911/11/11 is to be used, whenever the use of a drug, a treatment episode, etc., is known to have occurred but the date is unknown. Similarly, for other types of variables, there is most often a “yes/no” question, followed by the “date” question (for example: “Has the patient an AIDS diagnosis?” and then: “If yes, date of AIDS diagnosis”). For these types of questions, if the event is known to have occurred but the date is unknown, code the date as: 1911/11/11. Then the D:A:D validation programs will detect a ‘yes AIDS diagnosis’–‘unknown date of diagnosis’. If the only information available regarding a date is the year, then it should be entered as July 1, XXXX (XXXX/07/01). If the month and year are given, the date should be entered with the day being the 15<sup>th</sup> (XXXX/XX/15).

# 8 Data File Transfers to the D:A:D Co-ordinating Centre

Please utilize the HIV Distributed Data Management (HIV DDM) Tool for data submission at this 16th merger.

If unable to use the HIV DDM tool you should submit your data using SAS or ACCESS formats. SAS data sets are preferable—and SAS version 8 or 9 is preferable to version 6. ACCESS 2010, ACCESS 2007, ACCESS 2000 and ACCESS 1997 tables are also acceptable. Please sort each table by its key field(s). (The key fields are marked with an asterisk (\*) in the tables.)

In the event of data submission not using the HIV DDM tool, the data will be verified at the coordinating centre using the HIV DDM tool for a uniform QA procedure.

Please submit 14 or 15 raw data sets for this merger. (Submit the tbOVERLAP: Cross-Cohort Identification Table only if you have patients participating in other D:A:D cohorts.). The list of tables to submit is on the first page of the Appendix.

An ftp server (chip-crf.info) has been set-up with a password protected folder for each of the cohorts. Please contact Casper Møller Frederiksen ([casper.moeller.frederiksen@regionh.dk](mailto:casper.moeller.frederiksen@regionh.dk)) for you

username and password. Only you and the coordinating centre will have access to your folder. The other cohorts will not be able to look at your submitted data.

## 9 Error and Discrepancy Reporting

For this merger there may still be additional e-mails with material sent out within six weeks of data submission to the cohort data managers in order for them to check and correct their data and to replace “missing” values. This is in order to ensure we check all data items against all existing QA checks.

Please include the VERIFIED=1 variable for already verified outliers so that you will not spend time re-verifying these.

The cohort data managers should enter the corrected data into their own database and then re-run the DDM tool on the revised tables before sending the ExportData.mdb file to the D:A:D data manager. These revised tables will then be re-checked, and then, if there are no further problems, added to the rest of the cohort's data.

## Appendix

The following 15 tables describe the formats for the 16th merger data submission.

Shading is used to indicate changes and additions for the 16th merger.

Variables marked with an asterix (\*) are the key variables in each table. Taken in combination, this means that these variables must define a unique table entry.

1.	<b>tblBAS:</b>	Demographic, Clinical and Background Information
2.	<b>tblBAS_DAD:</b>	Enrolment
3.	<b>tblOVERLAP:</b>	Cross-Cohort Identification
4.	<b>tblVIS:</b>	Visit-related Data
5.	<b>tblVIS_DAD:</b>	Additional Visit-related Data
6.	<b>tblCEP:</b>	Clinical Events and Procedures
7.	<b>tblLAB_BP:</b>	Blood Pressure
8.	<b>tblLAB:</b>	Laboratory Values
9.	<b>tblLAB_CD4:</b>	CD4 Measurements
10.	<b>tblLAB_RNA:</b>	RNA Measurements
11.	<b>tblLAB_VIRO:</b>	Virology/Serology: Hepatitis and HIV-tests
12.	<b>tblART:</b>	Use of Anti-Retroviral Treatments
13.	<b>tblMED:</b>	Other HIV-Related and Cardiovascular Treatments
14.	<b>tblDIS:</b>	Severe Opportunistic Infections & Malignancies
15.	<b>tblLTFU:</b>	Lost to Follow-Up and Deaths



**1. tbIBAS: Demographic, Clinical and Background Information**

Explanation of variable	Code to identify patient	Code for clinic/ centre/ hospital where patient is seen.	Gender	Birth date	Patient's height [m]	Region of origin of patient	Region of origin of patient: other	Ethnicity/Race of patient	Date of enrolment in <u>local</u> cohort
Field name	<b>*PATIENT</b>	<b>CENTER</b>	<b>GENDER</b>	<b>BIRTH_D</b>	<b>HEIGHT</b>	<b>ORIGIN</b>	<b>ORI_OTH</b>	<b>ETHNIC</b>	<b>ENROL_D</b>
Format of data	Character 20	Character 20	1=Male 2=Female 9=Unknown	Date format	999=Unknown	See below for coding	Character 20	Numeric See below for coding	Date format

Explanation of variable	Mode of infection	Mode of infection: other	Date first seen at clinic	Date of seroconversion	Source of the SEROCO_D	Date of first HIV positive test	Has pt. an AIDS diagnosis	Date of AIDS diagnosis	Has pt. received antiretroviral treatment
Field name	<b>MODE</b>	<b>MODE_OTH</b>	<b>FRSVIS_D</b>	<b>SEROCO_D</b>	<b>SEROHOW</b>	<b>HIV_POS_D</b>	<b>AIDS_Y</b>	<b>AIDS_D</b>	<b>RECART_Y</b>
Format of data	Numeric See below for coding	Character 20	Date format	Date format	Numeric See below for coding	Date format	0=No 1=Yes 9=Unknown	Date format	0=No 1=Yes 9=Unknown

**2. tbIBAS\_DAD: Enrolment**

Explanation of variable	Code to identify patient	Cohort group identifier
Field name	<b>*PATIENT</b>	<b>ENROL</b>
Format of data	Character 20	1=I 2=II 3=III

1a. Code (bas_code_origin)	Region	Old codes
002	Africa	10, 2
015	Northern Africa	11, 21
	<del>Sub-Saharan Africa</del>	12, 22
014	Eastern Africa	12, 22
017	Middle Africa	12, 22
018	Southern Africa	12, 22
011	Western Africa	12, 22
142	Asia	20, 3
145	<del>Middle East</del> Western Asia	60, 7
009	Oceania ( <del>not Australia</del> )	30, 3
053	Australia & New Zealand	40, 5
054	Melanesia	30, 3
057	Micronesia	30, 3
061	Polynesia	30, 3
019	Americas	50, 6
021	North America	51, 61
	<del>Central &amp; South America</del>	52, 62
013	Central America	52, 62
005	South America	52, 62
150	Europe	70, 8
155	Western Europe	71, 81
151	Eastern Europe	72, 82
001	World <del>Unknown</del>	999, 99, 9

Please refer to <http://unstats.un.org/unsd/methods/m49/m49regin.htm> for any UN region codes not covered above and also to determine which countries belong to each of the regions.

1b. Code (bas_code_ethnic)	Ethnicity/Race
10	White
20	Black
21	<del>Sub-Saharan Africa-Black African</del>
22	Caribbean (Black Caribbean)
30	Hispanic/Latino/Latin American
40	Asian
41	Chinese
42	Southeast Asia (e.g. Thai, Vietnamese, Phillippino)
43	Indian Subcontinent (Indian, Pakastani, Bangladeshi)
44	Japanese
45	Other Asian
50	Indigenous people from Americas or Alaska Native (previously: American)
60	Indigenous people from other continents/locations (previously: Indigenous)
70	Other ethnic groups
71	Maghrebian
72	Middle East/Arabic
73	Turkish
74	Roma people/Gypsy (Whichever term is acceptable)
xyy(zz)	Mixed race/ethnicity. Combine 2-digits numbers from above (e.g. 1020 for white+black):

<b>1b. Code (bas_code_ethnic)</b>	<b>Ethnicity/Race</b>
1020	White-Black
1040	White-Asian
2030	Black-Hispanic
3040	Hispanic-Asian
102040	White-Black-Asian
97	Other
98	Prohibited
99	Unknown

<b>1c. Code (bas_code_mode)</b>	<b>Mode of infection</b>
1	homo/bisexual
2	injecting drug user
3	(1 + 2)
4	Haemophilic
5	transfusion, non-haemophilia related
6	heterosexual contact
7	(6 + 2)
8	Perinatal
90	other, (specify)
99	Unknown

<b>1d. Code (bas_code_serohow)</b>	<b>SEROHOW: Source of SEROCO_D</b>	<b>Old code</b>
1	Midpoint between last neg. and first pos. HIV-1 test	
2	Lab evidence of seroconversion	
3	Seroconversion illness	
4	Other	9,8
5	First pos HIV-1 test	4
9	Unknown	

<b>3. tbIOVERLAP: Cross-Cohort Identification</b>				
Explanation of Variable	Code to identify your D:A:D patient	Name of the cohort	Name of other D:A:D cohort	Unique patient identifier in other D:A:D cohort
Field name	<b>*PATIENT</b>	<b>*COHORT</b>	<b>*COH_OTH</b>	<b>PAT_OTH</b>
Format of data	Character 20	Character 20	Character 20	Character 20

<b>4. tblVIS: Visit-related Data</b>						
Explanation of variable	Code to identify patient	Visit date	Patient's weight [kg]	Is pt. experiencing fat loss from extremities, buttocks or face	Is pt. gaining fat in abdomen, neck, breast or other locations	Is the patient currently a smoker
Field name	<b>*PATIENT</b>	<b>*VIS_D</b>	<b>WEIGH</b>	<b>LOSS_Y</b>	<b>GAIN_Y</b>	<b>SMOKING_Y</b>
Format of data	Character 20	Date format	999=Un-known	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown

\* please note that SMK\_Y has been renamed to SMOKING\_Y and has moved from tblVIS\_DAD to tblVIS

<b>5. tblVIS_DAD: Additional Visit-related Data</b>					
Explanation of variable	Patient ID	Visit date	Was the patient ever a smoker	Is pt. experiencing lipodystrophy	First degree relative with AML before age 50
Field name	<b>*PATIENT</b>	<b>*VIS_D</b>	<b>SMD_Y</b>	<b>LIP_Y</b>	<b>FAM_Y</b>
Format of data	Character [20]	Date format	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown

Explanation of variable	Currently taking anti-platelets	Currently taking ACE inhibitors	Currently taking other anti-hypertensive agents	Currently taking lipid lowering agents	Currently taking oral anti-diabetic agents	Currently taking insulin or insulin derivatives	Currently taking anabolic steroids/appetite stimulants
Field name	<b>PLT_Y</b>	<b>ACE_Y</b>	<b>HYP_Y</b>	<b>LOW_Y</b>	<b>ORA_Y</b>	<b>INS_Y</b>	<b>ANA_Y</b>
Format of data	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown	0=No 1=Yes 9=Unknown

Please note that in submitting tblVIS\_DAD you are not required to submit the values regarding Cardiovascular Treatment (PLT\_Y, ACE\_Y, HYP\_Y, LOW\_Y, ORA\_Y, INS\_Y, ANA\_Y) if you have not at previous mergers been submitting the CAR table.

6. tblCEP: Adverse Events							
Explanation of Variable	Code to identify patient	Do not code! Unique event identifier	Event type	Further event type specification	Description of the event where the ae_id/ae_spec is not sufficient. For Cancers this could contain either the Location (example: lung) OR ICD10 code	Date of event	
Field name	*PATIENT	EVENT_ID	*CEP_ID	*CEP_SPEC	CEP_DESCRIP	*CEP_D	
Format of data	Character 20	Numeric	Character 4 See below	Character 4 See below	Character 50	Date format	

NB: Either the LOCATION or the ICD10 code should be provided where available, not both

6a. Coding for Adverse Event types		
CEP_ID	CEP_SPEC	Adverse Event
	LEIS	Leishmaniasis, visceral
	MCDI	Microsporidiosis diarrhoea (dur. > 1 month)
AMI		Acute Myocardial infarction
AMI	DAMI	Definitive Myocardial infarction
AMI	PAMI	Possible Myocardial infarction
STR		Stroke
STR	SHAE	Stroke: Haemorrhagia
STR	SINF	Stroke: Infarction
STR	SUNK	Stroke: Unknown
DIA		Diabetes mellitus
ICP		Invasive Cardiovascular Procedure
ICP	BYP	Coronary artery by-pass grafting
ICP	END	Carotid endarterectomy
ICP	ANG	Coronary angioplasty/stenting
CLD		<del>Chronic Liver Disease</del>
ESLD		End stage liver disease
ESRD		End stage renal disease
NADC		<del>Non-AIDS Defining Cancers</del>
NADM		Non-AIDS Defining Malignancies
NADM	ALL	Leukaemia: Acute lymphoid
NADM	AML	Leukaemia: Acute myeloid
NADM	ANUS	Anus cancer
NADM	BLAD	Bladder cancer
NADM	BONE	Bone cancer
NADM	BRAC	Brain cancer
NADM	BRCA	Breast cancer
NADM	CLL	Leukaemia: Chronic lymphoid
NADM	CML	Leukaemia: Chronic myeloid
NADM	COLO	Colon cancer
NADM	COTC	Connective tissue cancer
NADM	ESOP	Esophagus cancer

NADM	GALL	Gallbladder cancer
NADM	GYCA	Gynaecologic cancer
NADM	HENE	Head and neck (incl. face) cancers
NADM	HDL	Hodgkin lymphoma
NADM	KIDN	Kidney cancer
NADM	LEUK	Leukaemia: unspecified
NADM	LIPC	Lip cancer
NADM	LIVR	Liver cancer
NADM	LUNG	Lung cancer
NADM	MALM	Malignant melanoma
NADM	MEAC	Metastasis: of adenocarcinoma
NADM	MEOC	Metastasis: of other cancer type
NADM	MESC	Metastasis: of squamous cell carcinoma
NADM	META	Metastasis: unspecified
NADM	MULM	Multiple myeloma
NADM	PANC	Pancreas cancer
NADM	PENC	Penile cancer
NADM	PROS	Prostate cancer
NADM	RECT	Rectum cancer
NADM	STOM	Stomach cancer
NADM	TESE	Testicular seminoma
NADM	UTER	Uterus cancer
NADM	OTH	Non-Aids Defining Cancer: Other

**7. tbILAB\_BP: Blood Pressure**

Explanation of Variable	Code to identify patient	Date of Measurement	Systolic blood pressure [mmHg]	Diastolic blood pressure [mmHg]	Unit of measurement
Field name	<b>*PATIENT</b>	<b>*BP_D</b>	<b>BP_SYS</b>	<b>BP_DIA</b>	<b>BP_U</b>
Format of data	Character 20	Date format	Numeric	Numeric	Numeric

7a. Unit of measurement	Definition
1: mmHg	mmol/L
2: cmHg	cmHg
3: Kpa	Kpa

**8. tbILAB: Laboratory Values**

Explanation of Variable	Code to identify patient	Type of measurement	Specimen type (Glucose only)	Date of measurement	Measurement value	Unit of measurement	Measurement done while fasting	Verified LAB_V
Field name	<b>*PATIENT</b>	<b>*LAB_ID</b>	<b>*LAB_ST</b>	<b>*LAB_D</b>	<b>LAB_V</b>	<b>LAB_U</b>	<b>LAB_FA</b>	<b>VERIFIED</b>
Format of data	Character 20	Character 4 See coding below	Character 2 WB=Whole Blood P=Plasma S=Serum	Date format	Numeric (-1 = undetect. If detectable but under the threshold, then:- <value>)	Numeric <b>See coding below</b>	Numeric 0=No 1=Yes 9=Unknown blank for haemoglobin	Numeric 0=Not verified 1=Verified (by the provider of the data) 2=Plaus

								ible value(there are already extreme values in the past or there is a valuable explanation) 3=Cannot be verified (source document no more available)
--	--	--	--	--	--	--	--	---

8a. Code (lab_code)	Type of measurement
ALB	Albumin
ALT	Alanin-Aminotransferase
AST	Aspartat aminotransferase
BIL	Total Bilirubin
CHOL	Total cholesterol
CRE	Serum Creatinine
GLUC	Glucose
HAEM	Haemoglobin
HDL	Serum HDL
THR <del>PLT</del>	Thrombocytes <del>Platelet count</del>
TRIG	Serum triglyceride

8b. Measurement unit code (lab_code_units)	Definition
1	mmol/L
2	g/L
3	g/dL
4	mg/dL
5	Units/L
6	μmol/L
7	INR
8	1E+9/L
9	1E+6/L
10	cells/μL
11	μkat/L
12	%
13	μg/L
99	No unit (e.g. for Dipstick results)

9. tbILAB_CD4: CD4 Measurements				
Explanation of variable	Code to identify patient	Date of measurement	Measurement [counts/micro litre]	Verified LAB_V
Field name	*PATIENT	*CD4_D	CD4_V	VERIFIED
Format of data	Character 20	Date format	Numeric (-1 = undetectable; if	Numeric 0=Not verified

			detectable but under the threshold, then: - <value>)	1=Verified(by the provider of the data) 2=Plausible value(there are already extreme values in the past or there is a valuable explanation) 3=Cannot be verified (source document no more available)
--	--	--	--	---

Please note that we do not require the CD4\_U variable but you are welcome to provide it – we only collect counts/micro litre and not percent in D:A:D – we will just filter out the percentage values and not use them for D:A:D.

10. <b>tbILAB_RNA: RNA Measurements</b>						
Explanation of variable	Code to identify patient	Date of measurement	HIV-RNA measurement [copies/ml]	Lower limit of HIV-RNA assay [copies/ml]	Type of viral assay used for measurement	Verified LAB_V
Field name	*PATIENT	*RNA_D	RNA_V	RNA_L	RNA_T	VERIFIED
Format of data	Character 20	Date format	(-1 = undetectable; if detectable but under the threshold, then: - <value>)	999= unknown	Numeric See coding below	Numeric 0=Not verified 1=Verified(by the provider of the data) 2=Plausible value(there are already extreme values in the past or there is a valuable explanation) 3=Cannot be verified (source document no more available)

10a. Code (lab_rna_code_assay)	Viral assay used
5	Roche Taqman
10	Roche 1.0
15	Roche 1.5 ultra-sensitive
19	Any Roche (unspecified)
20	NASBA
21	NASBA ultra-sensitive
29	Any NASBA (unspecified)
31	Chiron b-DNA 1.0
32	Chiron b-DNA 2.0
33	Chiron b-DNA 3.0
39	Any Chiron (unspecified)
40	Abbott ultra-sensitive
41	Abbott LCx
42	Abbott Real time HIV M200
50	Monitor 1.0
51	Monitor 1.0 ultra-sensitive
55	Monitor 1.5
56	Monitor 1.5 ultra-sensitive
59	Monitor unspecified
65	Cobas 1.5



10a. Code (lab_rna_code_assay)	Viral assay used
66	Cobas 1.5 ultra-sensitive
90	Other
99	Unknown

### 11. tbILAB\_VIRO: Virology/Serology: Hepatitis and HIV-tests

Explanation of Variable	Code to identify patient	Viral test	Measurement date	Measurement result	Measurement value
Field name	*PATIENT	*VS_ID	*VS_D	VS_R	VS_V
Format of data	Character 20	Character 5 See coding below	Date format	0= negative 1= positive 9= unknown/ borderline	HCVR & HBVD only (-1 = undetectable; if detectable but under the threshold, then: -<value>)

Explanation of variable	Measurement unit	Lower limit of test	Upper limit of test	Type of viral test	Verified LAB_V
Field name	VS_U	VS_LL	VS_UL	VS_T	VERIFIED
Format of data	See coding below	999= unknown	999= unknown	Numeric See coding below	Numeric 0=Not verified 1=Verified(by the provider of the data) 2=Plausible value(there are already extreme values in the past or there is a valuable explanation) 3=Cannot be verified (source document no more available)

Please note that we now collect the HIV test results here to be able to determine last HIV-neg date. Please provide both first positive and last negative to be able to determine last negative test (collected in tbIBAS prior to 2013).

11a. Code (vs_id)	Viral test
HCV	Marker for hepatitis C infection - test unknown
HCVA	HCV antibody
HCVG	HCV antigen
HCVR	HCV-rna
HBV	Marker for hepatitis B infection (=HBVAC) - test unknown
HBVAS	HBV antibody (surface)
HBVAE	HBV antibody (envelope)
HBVAC	HBV antibody (core)
HBVGS	HBV antigen (surface)
HBVGE	HBV antigen (envelope)
HBVD	HBV-dna
HIV-1	HIV-1 test

HIV-2	HIV-2 test
HIVAE	HIV antibodies ELISA
HIVAWB	HIV antibodies Western blot

11b. Code (vs_u)	Test measurement unit
1	Copies/ml
2	IU/ml (International units/ml)
3	Geq (millions of genome equivalent)
4	pg/ml (picograms/ml)
9	Other

11c. Code (vs_t)	Viral test used
1	Roche qualitative (Amplicor) [HCV and HBV]
2	Roche quantitative test for HBV (Cobas Amplicor HBV monitor)
3	Bayer Bdna quantitative [HCV]
4	Bayer Bdna quantitative [HBV]
5	Roche Taqman
9	Other

12. tblART: Use of Anti-Retroviral Treatments					
Explanation of Variable	Code to identify patient	ATC code representing the antiretroviral treatment	Treatment start date	Treatment end date	Reason for stopping treatment
Field name	*PATIENT	*ART_ID	*ART_SD	ART_ED	ART_RS
Format of data	Character 20	Character 12	Date format	Date format	Numeric See coding below

If a new drug is used that does not appear in the lists in this SOP, then please refer to [http://www.whooc.no/atc\\_ddd\\_index/](http://www.whooc.no/atc_ddd_index/) for an updated list.

12a. Extended ATC codes (art_id)	Anti-Retroviral Drugs	Old codes
J05A	ART unspecified	
J05A-PBT	Participant in Blinded Trial	PBT
J05AE	PI unspecified	
J05AE-MOZ	Mozenavir (DMP-450)	
J05AE01	Saquinavir (gel, not specified)	SQV
J05AE01-SQH	Saquinavir hard gel (INVIRASE)	SQH
J05AE01-SQS	Saquinavir soft gel (FORTOVASE)	SQS
J05AE02	Indinavir (CRIXIVAN)	IDV
J05AE03	Ritonavir (NORVIR)	RTV
J05AE03-H	Ritonavir high dose (NORVIR)	
J05AE03-L	Ritonavir low dose (NORVIR)	
J05AE04	Nelfinavir (VIRACEPT)	NFV
J05AE05	Amprenavir (141W94) (AGENERASE)	APV
J05AE06	Lopinavir/Ritonavir (ABT-378/r, Kaletra)	ABT
J05AE07	Fosamprenavir (trial drug)	FSP, J05AE-FSP
J05AE08	Atazanavir (ZIRIVADA)	BMS, J05AE-ATV
J05AE09	Tipranavir (trial drug)	TPR, J05AE-TPR
J05AE10	Darunavir (TMC114) (PREZISTATM)	J05AE-TMC

J05AF	NRTI unspecified	
J05AF01	Zidovudine (AZT, RETROVIR)	AZT
J05AF02	Didanosine (ddI) (VIDEX)	DDI
J05AF03	Zalcitabine (ddC) (HIVID)	DDC
J05AF04	Stavudine (d4T) (ZERIT)	D4T
J05AF05	Lamivudine (3TC, EPIVIR)	TTC
J05AF06	Abacavir (1592U89) (ZIAGEN)	ABC
J05AF07	Tenofovir (VIREAD)	TEN
J05AF08	Adefovir (PREVEON)	ADE
J05AF09	Emtricitabine (trial drug)	FTC
J05AF10	Entecavir	
J05AF11	Telbivudine	
J05AF-ALO	Alovudine	
J05AF-AMD	Amdoxovir (DADP)	
J05AF30-COM	Zidovudine/Lamivudine - COMBIVIR (AZT/3TC, RETROVIR/EPIVIR)	COM
J05AF-FOZ	Fozivudine tidoxi	
J05AF30-KIV	Kivexa (3TC + ABC)	J05AF30-KVX
J05AF-LDN	Lodenoine (trialdrug)	
J05AF-RVT	Reverset	
J05AF30-TRU	Truvada	
J05AF30-TZV	Trizivir	TZV
J05AG	NNRTI unspecified	
J05AG01	Nevirapine (VIRAMUN)	NVP
J05AG02	Delavirdine (U-90152) (RESCRIPTOR)	DVL
J05AG03	Efavirenz (DMP-266) (STOCRIN, SUSTIVA)	EFV
J05AG04	Etravirine (TMC125)	J05AG-TMC
J05AG05	Rilpivirine (TMC-278)	
J05AG-CPV	Capravirine	
J05AG-DPC083	DPC083 (trial drug)	DPC
J05AG-DPC961	DPC 961	
J05AG-EMV	Emivirine (MKC442)	
J05AG-ETV	Etravirine (TMC 125)	
J05AG-LOV	Loviride	LOV
J05AG-RPV	Rilpivirine (TMC-278)	
J05AR01	Combivir (Zidovudine/Lamivudine)	
J05AR02	Kivexa (Lamivudine/Abacavir)	
J05AR03	Truvada (Tenofovir/Emtricitabine)	
J05AR04	Trizivir (Zidovudine/Lamivudine/Abacavir)	
J05AR05	Douvir-N (Zidovudine/Lamivudine/Nevirapine)	
J05AR06	Atripla (Emtricitabine/Tenofovir/Efavirenz)	
J05AR07	Triomune (stavudine, lamivudine and nevirapine)	
J05AR08	Complera, Eviplera (emtricitabine, tenofovir disoproxil and rilpivirine)	
J05AR09	Quad (emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat)	
J05AR10	Kaletra (lopinavir and ritonavir)	
J05AR11	Lamivudine, Tenofovir disoproxil and Efavirenz	
J05AR12	Lamivudine, tenofovir and disoproxil	
J05AR13	Lamivudine, abacavir and dolutegravir	
J05AR14	Darunavir and cobicistat	
J05AX07	Enfuvirtide (FUZEON, T-20/Ro 29-9800)	T20, ENF
J05AX08	Raltegravir (MK-0518)	

J05AX09	Maraviroc (UK427857)	J05AX-MVC
J05AX-CAB	Cabotegravir (GSK-744)	
J05AX-EVG	Elvitegravir (Gilead)	
J05AX11	Elvitegravir (Gilead)	
J05AX12	Dolutegravir	
J05AX-VIC	Vicriviroc	
L01XX05	Hydroxyurea/Hydroxycarbamid (LITALIR)	HYD
P02CB	Atervidine	ATV

12b. Code (art _rs)	Coding for Reason of Stopping Treatment
1	Treatment failure (i.e. virological, immunological, and /or clinical failure)
1.1	Virological failure
1.2	Partial virological failure
1.3	Immunological failure – CD4 drop
1.4	Clinical progression
2	Abnormal fat redistribution
3	Concern of cardiovascular disease
3.1	Dyslipidaemia
3.2	Cardiovascular disease
4	Hypersensitivity reaction
5	Toxicity, predominantly from abdomen/G-I tract
5.1	Toxicity – GI tract
5.2	Toxicity – Liver
5.3	Toxicity – Pancreas
6	Toxicity, predominantly from nervous system
7	Toxicity, predominantly from kidneys
8	Toxicity, predominantly from endocrine system
8.1	Diabetes
9	Haematological toxicity (anaemia ...etc.)
10	Hyperlactataemie/lactic acidosis
70	Pregnancy – toxicity concerns
75	Pregnancy – prevention of mother to child transmission
76	Post-partum prophylaxis
77	Dose change for height/ weight
88	Death
90	Side effects – any of the above but unspecified
90.1	Co morbidity
91	Toxicity, not mentioned above
91.1	Toxicity, unspecified
92	Availability of more effective treatment (not specifically failure or side effect related)
92.1	Simplified treatment available
92.2	Treatment to complex
92.3	Drug interaction
92.31	Drug interaction - commencing TB/BCG treatment
92.32	Drug interaction - ended TB/BCG treatment
92.33	Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available)
92.4	Protocol change
92.9	Change in treatment not due to side-effects, failure, poor adherence or contra-indication

93	Structured Treatment Interruption (STI)
93.1	Structured Treatment Interruption (STI) – at high CD4
94	Patient's wish/ decision, not specified above
94.1	Non-compliance
94.2	Defaulter
95	Physician's decision, not specified above
96	Pregnancy
96.1	Pregnancy intended
96.2	Pregnancy ended
97	Study treatment
97.1	Study treatment commenced
97.2	Study treatment completed
97.6	Drug not available
98	Other causes, not specified above
99	Unknown

<b>13. tbIMED: Other HIV-Related and Cardiovascular Treatments</b>					
Explanation of variable	Code to identify patient	ATC treatment code	Treatment start date	Treatment end date	Reason for stopping treatment
Field name	<b>*PATIENT</b>	<b>*MED_ID</b>	<b>*MED_SD</b>	<b>MED_ED</b>	<b>MED_RS</b>
Format of data	Character 20	Character 12 See coding below	Date format	Date format	Numeric See coding below

If a new drug is used that does not appear in the lists in this SOP, then please refer to [http://www.whocc.no/atc\\_ddd\\_index/](http://www.whocc.no/atc_ddd_index/) for an updated list, this is also the reference for the full ATC codes for drugs. **If you have a more precise ATC code for a drug that only has a partial ATC code in the list below, please provide the more precise code.**

<b>13a. Extended ATC codes (med_id)</b>	<b>Treatments</b>
	<b>Influencing Cardiovascular Risk</b>
B01AC	Anti-platelets (PLT)
C09	ACE inhibitors (ACE)
C-HYP	Other anti-hypertensive agents (HYP) [C02, C03, C04, C07,C08]
C10	Lipid lowering agents (LOW)
A10B	Anti-diabetic agents (ORA)
A10A	Insulin/ insulin derivatives (INS)
A14A	Anabolic steroids/ appetite stimulants (ANA)
	<b>Other HIV-Related Treatments</b>
J01EA01	Trimethoprim
J01EC02	Sulfadiazine
J01EE	Cotrimoxazole (BACTRIM, EUSAPRIM, NOFIL)
J01EE01	Sulfamethoxazole and trimethoprim (Bactrim)
J01EE03	Sulfametrole and trimethoprim - Cosoltrime (MADERAN)
J01FA09	Clarithromycine (KLACID)
J01FA10	Azithomycine (ZITHROMAX)
J01FF01	Clindamycine
J01GB06	Amikacine (AMIKINE)
J01MA02	Ciprofloxacin (CIPROXINE, CILOXAN)
J01MA12	Levofloxacin (TAVANIC)
J01MA14	Moxifloxacin
J01RA02	Cosoltrime (MADERAN)
J02AA01	Amphotericin B (FUNGIZON)
J02AB	Imidazoles (DAKTARIN, NIZORAL, PEVARYL ...)
J02AB02	Ketoconazole
J02AC01	Fluconazole (DIFLUCAN)
J02AC02	Itraconazole (SPORANOX)
J02AC03	Voriconazole
J02AC04	Posaconazole
J02AX01	Flucytosine
J04AB02	Rifampin (RIMATICIN)
J04AB04	Rifabutin (MYCOBUTIN)
J04AC01	Isoniazide (RIMIFON)
J04AK01	Pyrazinamide (PYRAZINAMID)
J04AK02	Ethambutol (EMB, MYAMBUTOL)

J04AM02	RIFATER
J04AM05	RIFATER
J04BA01	Clofazimine (LAMPREN)
J04BA02	Dapsone
J05AB01	Aciclovir (ZIVORAX)
J05AB04	Ribavirin
J05AB06	Ganciclovir (CYMEVENE)
J05AB09	Famciclovir
J05AB11	Valaciclovir (VALTEX)
J05AB12	Cidofovir (VISTIDE)
J05AB15	Valganciclovir
J05AD01	Foscarnet (FOSCAVIR)
J05AE12	Boceprevir (Victrelis)
J05AE11	Telaprevir (Incivek)
J05AE13	Faldaprevir
J05AE14	Simeprevir
J05AE15	Asunaprevir
J05AX14	Daclatasvir
J05AX15	Sofosbuvir
J05AX16	Dasabuvir (EXVIERA)
J05AX65	Sofosbuvir and ledipasvir (HARVONI)
J05AX67	Ombitasvir, paritaprevir and ritonavir (VIEKIRAX)
J05AR-A450OM	ABT-450/r/Ombitasvir
J05AR-DAAS	Daclatasvir/Asunaprevir
J05AR-LESO	Ledipasvir/Sofosbuvir
J05AR-DBV	Dasabuvir
J05AF10	Entecavir
J05AF11	Telbivudine
L01AA01	Cyclophosphamide (ENDOXAN)
J01AA08	Minocycline (MINOCIN)
L01AD02	CCNU (LOMUSTINE)
L01AX04	Dacabazine (DTIC - Dome)
L01BA01	Methotrexate
L01CA01	Vinblastin (VELBE)
L01CA02	Oncovin (VINCRISTINE)
L01CB01	Etoposide (VEPESIDE, EXITOP 100)
L01DB01	Doxil (CAELYX) Doxorubicine, Adriamycine (ADRIBLASTIN)
L01DC01	Bleomycine
L01XB01	Procarbazine (NATULAN)
L03AA02	2 G-CSF
L03AB	Interferon
L03AB-AL2	Peginterferon alfa-2a/alfa-2b (PEGINTRON, PEGASYS)
L03AB10	Peginterferon alfa-2b (PEGINTRON)
L03AB11	Peginterferon alfa-2a (PEGASYS)
L03AC-IL2	Interleukin 2
P01AX06	Atovaquone (WELLVONE, MEPRONE)
P01BA03	Primaquine
P01BD01	Pyrimethamine (DARAPRIM)
P01BD51	Pyrimethamine/Sulfadoxine (FANSIDAR)
P01BD-SUX	Sulfadoxine
P01CX01	Pentamidine aerosol (PENTACARNET)

V03AF03	Folate of calcium (LEUCOVORINE)
J01	Antibiotics
H02	Corticosteroids
G02CA	Tocolysis

<b>13b. Code (med_rs)</b>	<b>Coding for Reason of Stopping Treatment</b>
1	Treatment failure (i.e. virological, immunological, and /or clinical failure)
1.1	Virological failure
1.2	Partial virological failure
1.3	Immunological failure – CD4 drop
1.4	Clinical progression
2	Abnormal fat redistribution
3	Concern of cardiovascular disease
3.1	Dyslipidaemia
3.2	Cardiovascular disease
4	Hypersensitivity reaction
5	Toxicity, predominantly from abdomen/G-I tract
5.1	Toxicity – GI tract
5.2	Toxicity – Liver
5.3	Toxicity – Pancreas
6	Toxicity, predominantly from nervous system
7	Toxicity, predominantly from kidneys
8	Toxicity, predominantly from endocrine system
8.1	Diabetes
9	Haematological toxicity (anaemia ...etc.)
10	Hyperlactataemia/lactic acidosis
70	Pregnancy – toxicity concerns
75	Pregnancy – prevention of mother to child transmission
76	Post-partum prophylaxis
77	Dose change for height/ weight
88	Death
90	Side effects – any of the above but unspecified
90.1	Co morbidity
91	Toxicity, not mentioned above
91.1	Toxicity, unspecified
92	Availability of more effective treatment (not specifically failure or side effect related)
92.1	Simplified treatment available
92.2	Treatment to complex
92.3	Drug interaction
92.31	Drug interaction - commencing TB/BCG treatment
92.32	Drug interaction - ended TB/BCG treatment
92.33	Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available)
92.4	Protocol change
92.9	Change in treatment not due to side-effects, failure, poor adherence or contra-indication
93	Structured Treatment Interruption (STI)
93.1	Structured Treatment Interruption (STI) – at high CD4
94	Patient's wish/ decision, not specified above
94.1	Non-compliance



94.2	Defaulter
95	Physician's decision, not specified above
96	Pregnancy
96.1	Pregnancy intended
96.2	Pregnancy ended
97	Study treatment
97.1	Study treatment commenced
97.2	Study treatment completed
97.6	Drug not available
98	Other causes, not specified above
99	Unknown

#### 14. tbIDIS: Severe Opportunistic Infections & Malignancies

Explanation of variable	Code to identify patient	Event identification	Event date	Means of diagnosis
Field name	*PATIENT	*DIS_ID	*DIS_D	DIS_WD
Format of data	Character 20	Character 4 See coding below	Date format	Numeric See coding below

14a. Code (dis_id)	Severe Opportunistic Infections
DEM	AIDS dementia complex
BCNE	Bacterial pneumonia, recurrent (>2 episodes within 1 year)
CANO	Candidiasis, oesophageal
CRCO	Cryptococcosis, extrapulm.
CRSP	Cryptosporidiosis (duration > 1 month)
CMVR	Cytomegalovirus (CMV) chorioretinitis
CMVO	CMV – other location
HERP	Herpes simplex virus ulcers (duration > 1 month) or pneumonitis/esophagitis
HIST	Histoplasmosis, extrapulm.
WAST	HIV Wasting Syndrome
ISDI	Isosporiasis diarrhoea (duration > 1 month)
LEIS	Leishmaniasis, visceral Use tbICEP instead
MCDI	Microsporidiosis diarrhoea (dur. > 1 month) Use tbICEP instead
MC	Mycobact. avium complex (MAC) or Kanasii, extrapulm.
MCP	Mycobact. tuberculosis pulm.
MCX	Mycobact. tuberculosis extrapulm
MCPO	Mycobact. pulm. , other
MCXO	Mycobact. extrapulm. , other
PCP	Pneumocystis carinii pneumonia (PCP)
LEU	Progressive multifocal leucoencephalopathy
SAM	Salmonella bacteraemia (non-typhoid) (> 2 episodes/recurrent)
TOX	Toxoplasmosis, brain
FBLS	Focal Brain lesion
	<b>Malignancies</b>
KS	Kaposi Sarcoma
NHG	Non-Hodgkin Lymphoma -not specified
NHGB	Non-Hodgkin Lymphoma –Burkitt
NHGI	Non-Hodgkin Lymphoma –Immunoblastic
NHGU	Non-Hodgkin Lymphoma -Unknown/other histology
NHGP	Non-Hodgkin Lymphoma -Primary Brain Lymphoma

CRVC	Cervical Cancer
<del>CRVD</del> -CERV	Cervical Dysplasia/ carcinoma in situ

14b. Code (dis_wd)	Means of diagnosis
1	Definitive diagnosis
2	Presumptive diagnosis
3	Diagnosis from autopsy
4	Diagnosis from registry

<b>15. tbILTFU: Lost to Follow-Up and Deaths</b>				
Explanation of variable	Code to identify patient	Has patient dropped out	If dropped out, last contact date	Reason for dropping out
Field name	<b>*PATIENT</b>	<b>DROP_Y</b>	<b>DROP_D</b>	<b>DROP_RS</b>
Format of data	Character 20	0=No 1=Yes	Date format	Numeric See below for coding

Explanation of variable	Has patient died	Death date	Primary underlying cause of death	Coding of causal relation of the code given in DEATH_R1 to the death	Coding of certainty of diagnosis given in DEATH_R1	Was an autopsy performed
Field name	<b>DEATH_Y</b>	<b>DEATH_D</b>	<b>DEATH_R1</b>	<b>DEATH_RC1</b>	<b>DEATH_RDC1</b>	<b>AUTOP_Y</b>
Format of data	0=No 1=Yes	Date format	Numeric See below for coding	Character See below for coding	Character See below for coding	0=No 1=Yes 9=Unknown

Feel free to provide additional DEATH\_Rx, DEATH\_RCx and DEATH\_RDCx values as suggested in HICDEP. In support of the CoDe coding scheme the fields DEATH\_RC1 and DEATH\_RDC1 have been added. Please code it “N” for “not available” if you do not collect this information.

<b>15a. Code (DROP_RS)</b>	<b>Reason for dropping out</b>	<b>Old code</b>
1	Patient lost to follow-up / Not known to be dead	1
2	Patient has not had visit within required amount of time	2
2.1	Patient did not respond to several invitations	
3	Patient moved away	3
3.1	Patient moved to another country	
4	Patient moved and is followed by another centre	4
4.1	Paediatric patient transferred to adult care	
5	Patient's decision	5
5.1	Patients caretaker wanted to discontinue (for children)	
6	Consent withdrawn	
7	Incarceration/jail	6
8	Institutionalisation (drug treatment, psychological ...etc.)	7
9	Other	8

<b>15b. Code (DEATH_R1)</b>	<b>Primary underlying cause of death (Additional event form may be required for D:A:D events)</b>	<b>Old code</b>
1	AIDS (ongoing active disease)	7
1.1	Infection	7
1.11	Tuberculosis	
1.111	Pulmonary tuberculosis	
1.112	Extrapulmonary TB	
1.11201	Pleura (isolated, without lungs involvement)	
1.11202	Lymphatic intrathoracic (isolated, without lungs involvement)	
1.11203	Lymphatic extrathoracic	
1.11204	Pericardia	
1.11205	Spine	
1.11206	Bone/joints other than spine	
1.11207	Meningitis	
1.11208	CNS other than meningitis	
1.11209	Genito-urinary tract	

1.1121	Peritoneal/digestive	
1.11211	TB with poly-organ failure/ TB sepsis	
1.113	Disseminated tuberculosis	
1.11301	Lungs	
1.11302	Miliary	
1.11303	Pleura	
1.11304	Lymphatic intrathoracic	
1.11305	Lymphatic extrathoracic	
1.11306	Pericardia	
1.11307	Spine	
1.11308	Bone/joints other than spine	
1.11309	Meningitis	
1.1131	CNS other than meningitis	
1.11311	Genito-urinary tract	
1.11312	Peritoneal/digestive	
1.11313	TB with poly-organ failure/ TB sepsis	
1.12	other AIDS-defining infection	
1.121	with lungs involvement	
1.122	with CNS involvement	
1.2	Malignancy	7
1.2.1	AIDS Malignancy localised to lungs	
1.3	IRIS and cART initiation (can only be used as contributing cause of death)	
2	Infection (other than 01.1)	
2.1	Bacterial	
2.11	Bacterial with sepsis	
2.12	Bacterial pneumonia	
2.13	Bacterial meningitis	
2.2	Others	
2.21	Others with sepsis	
2.22	Other pneumonia	
2.23	Other with CNS involvement	
2.3	Unknown aetiology	
2.31	Unknown with sepsis	
3	Chronic viral hepatitis (progression of/complication to)	6
3.1	HCV	6
3.11	HCV with cirrhosis	6
3.12	HCV with liver failure	6
3.13	HCV with liver cancer	
3.2	HBV	6
3.21	HBV with cirrhosis	6
3.22	HBV with liver failure	6
3.23	HBV with liver cancer	
4	Malignancy (other than 01.2 and 03, 03.1, 03.2)	17
4.03	ANUS – Anal cancer	
4.04	BLAD – Bladder cancer	
4.05	BONE – Bone cancer	
4.06	BRAC – Brain cancer	
4.07	BRCA – Breast cancer	
4.101	ALL – Leukaemia: Acute lymphoid	
4.102	AML – Leukemia: Acute myeloid	
4.103	CLL – Leukemia: Chronic lymphoid	
4.104	CML – Leukemia: Chronic myeloid	
4.109	LEUK – Leukemia: unspecified	
4.18	COLO – Colorectal cancer	

4.11	COC – Connective tissue cancer	
4.12	ESOP Esophagus cancer	
4.13	GALL – Gallbladder cancer	
4.14	GYCA – Gynaecologic cancer	
4.15	HDL – Hodgkin lymphoma	
4.16	HENE – Head and neck (incl. face) cancer	
4.17	KIDN – Kidney cancer	
4.19	LIPC – Lip cancer	
4.20	LIVR – Liver cancer	
4.21	LUNG – Lung cancer	
4.22	MALM – Malignant melanoma	
4.27	MULM – Multiple myeloma	
4.29	PANC – Pancreas cancer	
4.31	PENC - Penile cancer	
4.32	PROS – Prostate cancer	
4.33	RECT – Rectum cancer	
4.34	STOM – Stomach cancer	
4.35	TESE - Testicular cancer	
4.36	UTER – Uterus cancer	
4.401	MEAC – Metastasis: of adenocarcinoma	
4.402	MEOC – Metastasis: of other cancer types	
4.403	MESC – Metastasis: of squamous cell carcinoma	
4.409	META – Metastasis: unspecified	
4.90	OTH – Other Malignancy Type	
4.99	UNKP – Unknown Malignancy Type	
5	Diabetes Mellitus (complication to)	4
6	Pancreatitis	5
7	Lactic acidosis	3
8	MI or other ischemic heart disease	
8.1	AMI	1
8.11	Definitive AMI (Dundee 1)	
8.12	Possible AMI (Dundee 2/9)	
8.2	Other ischemic heart disease	2
9	Stroke	1
10	Gastro-intestinal haemorrhage (if chosen, specify underlying cause)	
11	Primary pulmonary hypertension	
12	Lung embolus	
13	Chronic obstructive lung disease	
14	Liver failure (other than 03, 03.1, 03.2)	3
15	Renal failure	
16	Accident or other violent death (not suicide)	
17	Suicide	8
18	Euthanasia	
19	Substance abuse (active)	10
19.1	Chronic Alcohol abuse	10
19.2	Chronic intravenous drug-use	10
19.3	Acute intoxication	10
19.31	Toxicity to anti-TB drugs	
20	Haematological disease (other causes)	
21	Endocrine disease (other causes)	
22	Psychiatric disease (other causes)	
22.1	Mental and behavioural disorders due to use of psychoactive substances (other than alcohol and intravenous opioids)	
22.2	Schizophrenia, schizotypal and delusional Disorders	

22.3	Mood /Affective disorders (Major depressive disorder, Bipolar disorder and other mood disorders)	
22.4	Epilepsy (including localised and generalized epilepsy and epileptic syndromes)	
22.5	Polyneuropathies (Guillain–Barré syndrome and other polyneuropathies/disorders of the peripheral nervous system)	
22.90	Other psychiatric disorders	
23	CNS disease (other causes)	
23.1	Movement disorders (Parkinson's disease; dystonias and Parkinson-like syndromes)	
23.2	Degenerative disorders of the central nervous system (Alzheimer's disease; Creutzfeldt-Jakob disease and other degenerative diseases of nervous system)	
23.3	Demyelinating diseases of the central nervous system (Multiple sclerosis, other demyelinating diseases)	
23.4	Epilepsy (including localised and generalized epilepsy and epileptic syndromes)	
23.5	Polyneuropathies (Guillain-Barré syndrome and other polyneuropathies/disorders of the peripheral nervous system)	
23.6	Diseases of myoneural junction and muscle (Miastenia gravis and other myoneural disorders)	
23.90	Other disorders of the nervous system	
24	Heart or vascular (other causes)	2
25	Respiratory disease (other causes)	
26	Digestive system disease (other causes)	
27	Skin and motor system disease (other causes)	
28	Urogenital disease (other causes)	
29	Obstetric complications	
30	Congenital disorders	
31	Symptoms caused by mitochondrial toxicity (other than 06, 07)	3
32	Bleeding (haemophilia)	
33	Sudden infant death	
33.1	Child abuse	
90	Other causes	12
91	Unclassifiable causes	99
92	Unknown	99
92.1	Unknown, Competing risks	

15c. Code (DEATH_RC1)	Coding of causal relation to the death
I	Immediate cause
U	Underlying cause/condition
C	Contributing cause
N	Not available

15d. Code (DEATH_RDC1)	Certainty of diagnosis
D	Definite: 95-100% certainty
L	Likely: 80-95% certainty
P	Possible: 50-80% certainty
N	Not available